A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics.
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Benralizumab (Primary)
- Indications Allergic asthma
- Focus Registrational; Therapeutic Use
- Acronyms ARIA
- Sponsors AstraZeneca
- 02 Mar 2017 Planned End Date changed from 1 Feb 2019 to 11 Feb 2019.
- 02 Mar 2017 Planned primary completion date changed from 1 Feb 2019 to 11 Feb 2019.
- 14 Oct 2016 Status changed from not yet recruiting to recruiting.